Biotech Values

[DewDiligence]

Roche’s crenezumab is first AD drug to be tested on humans with no signs of dementia:

http://in.reuters.com/article/2012/05/15/us-alzheimers-genentech-idINBRE84E0UJ20120515

The drug will be tested among members of an extended family of about 5,000 people from the Antioquia region of Colombia. They carry a gene that causes them to develop Alzheimer's early, with some experiencing symptoms of memory loss in their mid-30s, scientists say.

The U.S. Department of Health & Human Services is backing the trial with a $16 million grant as part of the government's National Alzheimer's Plan announced on Tuesday… Another $15 million in trial funding comes from Banner Health, a non-profit organization based in Phoenix, Arizona, that runs a chain of hospitals and which is leading the study. The rest of an estimated $100 million in total costs will be paid by [Roche]…